Public and Government Affairs Charter

Mission of Public and Government Affairs at bioMérieux

At bioMérieux (the “Company”), we believe that our dedication to public health and our expertise in infectious diseases give us the responsibility to work towards a transparent, productive, and ethical dialogue between the private and public sectors to improve the health and safety of patients and consumers.

For bioMérieux, Public and Government Affairs Activities (“Activities”) refers to a structured, strategic process that promotes in vitro diagnostics and its medical economic value as a key to better public health. This process represents the long-term interests of the Company with public decision-makers through bidirectional, principled, and balanced information. This Public and Government Affairs Charter (“Charter”) has been created to ensure that the Activities are in full alignment with the Company’s commitment to integrity.

We aim to work together and transparently with public representatives to advance legislation and regulations so that the needs and specificities of the in vitro diagnostics industry, as well as the needs of patients and consumers, can be taken into account in governmental actions.

Application of this Charter

At bioMérieux, Activities should only be executed by those authorized to do so.

Any authorized individuals, whether internal or external, must abide by this Charter, which is publicly available. Authorized individuals, whether internal or external, must certify their adherence to this document prior to engaging in these Activities.

Governance of Activities

The priorities for Activities are set by the Company at the executive management level (Executive Committee of bioMérieux) to align with the Company’s business strategy. The Public and Government Affairs Department is responsible for developing advocacy strategies and position papers to support corporate and local Activities in line with these priorities. In addition, the Public and Government Affairs Department manages and coordinates bioMérieux’s participation in relevant industry associations (in particular AdvaMed, MedTech Europe, and SiDIV).

Any individual engaging in Activities must represent bioMérieux’s interest in alignment with this structure. Activities must conform to internally-disclosed position papers issued by the Public and Government Affairs Department and this Charter.
Commitments

bioMérieux has a strong reputation, based on values handed down through generations. To maintain this reputation, we operate within a framework of principles, directives, and procedures that reflect the highest standards of integrity. To ensure that our Activities reflect our ethics, all authorized individuals commit to the following:

- **Respect for bioMérieux Policies and Procedures.** The Code of Conduct and other policies, including the Corruption Prevention Manual, must be strictly followed.

- **Compliance and Integrity.** All representatives must obey all applicable laws and regulations where they are operating. Special attention must be given to local lobbying regulations that may govern the nature and number of interactions that Company representatives may have with government representatives. All authorized individuals must know and abide by their local regulations.

- **Transparency.** All representatives must disclose to decision-makers their name, affiliation with bioMérieux (role and position), and the interests they represent on behalf of the Company, in alignment with position papers.

- **Registration of individuals or activities.** The definition of “lobbyist” varies and may include Activities in some jurisdictions. Where required by law, the local registration process for lobbying must be respected by the relevant bioMérieux subsidiary and authorized individuals. A local process must be put in place to ensure the respect of these regulations. Such registrations must be shared with the Public and Government Affairs Department and Ethics & Compliance.

- **Fair and Balanced Information.** bioMérieux representatives commit to presenting information in a truthful, balanced way. Exaggerated, false or misleading information must not be shared. The source of information must be explicitly stated or easily identified.

- **Avoid Conflicts of Interest.** Representatives must avoid any personal interests that may interfere with their objective representation of bioMérieux’s interests. Any close personal or professional relationship, as well as any business or financial relationship with a public office holder, could present a conflict of interest. Any potential conflicts of interest must be disclosed in accordance with bioMérieux’s Conflicts of Interest Policy. There must be no abuse of positions or relationships with public authorities or any other kind of improper influence for personal benefit or for the benefit of bioMérieux. Authorized individuals must not accept political position/appointment.

- **Zero tolerance for Corruption.** As stated in our Corruption Prevention Manual, bioMérieux is committed to conducting its activities free from the unfair influence of bribery and corruption. bioMérieux representatives, whether internal or external, must never give, promise, or offer anything of value to obtain an improper or illegal advantage, and never authorize anyone else to do these things on the Company’s behalf.

- **No political contributions.** It is bioMérieux’s policy not to support directly (contributions) or indirectly (purchase or supply of goods or services) any local, national or international political campaigns, parties, politicians, or related institutions.

- **Confidentiality.** Representatives respect all applicable rules, standards, or conventions governing the disclosure or nondisclosure of information shared in the context of Activities. Confidential information received must only be shared in accordance with these agreed upon standards. Internal confidential information may only be shared with appropriate authorization from the Executive Committee.

Implementation

This document will be regularly reviewed and amended. It has been adopted by the Public and Government Affairs Department, as well as the Ethics & Compliance Department and the Legal Department.

02/2021